Expression of cell cycle biomarkers and telomere length in papillary thyroid carcinoma: A comparative study between radiation-associated and spontaneous cancers

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 32, Issue 1, 2009, Pages 1-8

  Achille, Mihaela ^a,b   Boukheris, Houda ^c   Caillou, Bernard ^b   Talbot, Monique ^b   De Vathaire, Florent ^c   Sabatier, Laure ^a   Desmaze, Chantal ^a   Schlumberger, Martin ^b   Soria, Jean Charles ^a,b  

^a DIF   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c INSERM   (France)

Author keywords

Cyclins; Papillary thyroid carcinoma; Radiation associated; Telomere length

Indexed keywords

CYCLIN A; CYCLIN B1; CYCLIN D1; CYCLIN E; KI 67 ANTIGEN; CELL CYCLE PROTEIN;

ADULT; AGED; ARTICLE; CELL CYCLE; CHILD; CHROMOSOME SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; PRESCHOOL CHILD; PROTEIN EXPRESSION; RADIATION CARCINOGENESIS; SCHOOL CHILD; TELOMERE; THYROID CARCINOMA; ADENOCARCINOMA; ADOLESCENT; CASE CONTROL STUDY; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; INFANT; METABOLISM; MIDDLE AGED; PAPILLARY CARCINOMA; PATHOLOGY; PROGNOSIS; RADIATION INJURY; THYROID TUMOR; TISSUE MICROARRAY;

ADENOCARCINOMA, FOLLICULAR; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PAPILLARY; CASE-CONTROL STUDIES; CELL CYCLE PROTEINS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; MALE; MIDDLE AGED; NEOPLASMS, RADIATION-INDUCED; PROGNOSIS; TELOMERE; THYROID NEOPLASMS; TISSUE ARRAY ANALYSIS; YOUNG ADULT;

EID: 60549094086     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181783336     Document Type: Article

References (37)

1. United Nations Scientific Committee on the Effects of Atomic Radiation. Sources and effects of ionizing radiation: 2000, report to the General Assembly, with scientific annexes; Vol. II: Effects. 2000.
2. Wood JW, Tamagaki H, Neriishi S, et al. Thyroid carcinoma in atomic bomb survivors Hiroshima and Nagasaki. Am. J. Epidemiol. 1969;89:4-14..
3. Preston DL, Ron E, Tokuoka S, et al. Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat Res. 2007;168:1-64.
4. Ron E, Lubin JH, Shore RE, et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res. 1995; 141:259-277.
5. United Nations Scientific Committee on the Effects of Atomic Radiation. United Nations Scientific Committee on the effects of atomic radiation. Sources, effects and risks of ionizing radiation, with annexes. 2000.
6. Schneider AB, Ron E. Carcinoma of follicular epithelium: pathogenesis. In: Braverman LE, Utiger RD, eds. The Thyroid. Philadelphia, PA: Lippincott-Raven; 1996:902-909.
7. Rubino C, Cailleux AF, de VF, et al. Thyroid cancer after radiation exposure. Eur J Cancer. 2002;38:645-647.
8. Bounacer A, Wicker R, Caillou B, et al. High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene. 1997;15:1263-1273.
9. Ciampi R, Knauf JA, Kerler R, et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest. 2005;115:94-101.
10. Fagin JA. How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J Endocrinol. 2004;183:249-256.
11. Melillo RM, Castellone MD, Guarino V, et al. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest. 2005;115:1068-1081.
12. Detours V, Wattel S, Venet D, et al. Absence of a specific radiation signature in post-Chernobyl thyroid cancers. Br J Cancer. 2005;92:1545-1552.
13. Ito Y, Yoshida H, Nakano K, et al. Expression of G2-M modulators in thyroid neoplasms: correlation of cyclin A, B1 and cdc2 with differentiation. Pathol Res Pract. 2002;198:397-402.
14. Ito Y, Yoshida H, Nakano K, et al. Expression of cdc25A and cdc25B proteins in thyroid neoplasms. Br J Cancer. 2002;86:1909-1913.
15. Basolo F, Caligo MA, Pinchera A, et al. Cyclin D1 overexpression in thyroid carcinomas: relation with clinico-pathological parameters, retino-blastoma gene product, and Ki67 labeling index. Thyroid. 2000;10:741-746.
16. Lee CC, Yamamoto S, Morimura K, et al. Significance of cyclin D1 overexpression in transitional cell carcinomas of the urinary bladder and its correlation with histopathologic features. Cancer. 1997;79:780-789.
17. Nielsen NH, Emdin SO, Cajander J, et al. Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein. Oncogene. 1997;14:295-304.
18. Pickett CA, Agoff SN, Widman TJ, et al. Altered expression of cyclins and cell cycle inhibitors in papillary thyroid cancer: prognostic implications. Thyroid. 2005;15:461-473.
19. Wang S, Lloyd RV, Hutzler MJ, et al. The role of cell cycle regulatory protein, cyclin D1, in the progression of thyroid cancer. Mod Pathol. 2000; 13:882-887.
20. Nakashima M, Meirmanov S, Naruke Y, et al. Cyclin D1 overexpression in thyroid tumours from a radio-contaminated area and its correlation with Pin1 and aberrant beta-catenin expression. J Pathol. 2004;202:446-455.
21. Brzezinski J, Migodzinski A, Gosek A, et al. Cyclin E expression in papillary thyroid carcinoma: relation to staging. Int J Cancer. 2004;109:102-105.
22. Brzezinski J, Migodzinski A, Toczek A, et al. Patterns of cyclin E, retinoblastoma protein, and p21Cip1/WAF1 immunostaining in the oncogenesis of papillary thyroid carcinoma. Clin Cancer Res. 2005;11:1037-1043.
23. Keyomarsi K, Tucker SL, Buchholz TA, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med. 2002;347:1566-1575.
24. Lantuejoul S, Soria JC, Morat L, et al. Telomere shortening and telomerase reverse transcriptase expression in preinvasive bronchial lesions. Clin Cancer Res. 2005;11:2074-2082.
25. Meeker AK, Hicks JL, Iacobuzio-Donahue CA, et al. Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin Cancer Res. 2004;10:3317-3326.
26. Haugen BR, Nawaz S, Markham N, et al. Telomerase activity in benign and malignant thyroid tumors. Thyroid. 1997;7:337-342.
27. Lazzereschi D, Sambuco L, Carnovale SC, et al. Cyclin D1 and Cyclin E expression in malignant thyroid cells and in human thyroid carcinomas. Int J Cancer. 1998;76:806-811.
28. Matthews P, Jones CJ, Skinner J, et al. Telomerase activity and telomere length in thyroid neoplasia: biological and clinical implications. J Pathol. 2001;194:183-193.
29. Wang S, Wuu J, Savas L, et al. The role of cell cycle regulatory proteins, cyclin Dl, cyclin E, and p27 in thyroid carcinogenesis. Hum Pathol. 1998; 29:1304-1309
30. Hassan KA, El-Naggar AK, Soria JC, et al. Clinical significance of cyclin B1 protein expression in squamous cell carcinoma of the tongue. Clin Cancer Res. 2001;7:2458-2462.
31. Kawamoto H, Koizumi H, Uchikoshi T. Expression of the G2-M checkpoint regulators cyclin B1 and cdc2 in nonmalignant and malignant human breast lesions: immunocytochemical and quantitative image analyses. Am J Pathol. 1997;150:15-23.
32. Mashal RD, Lester S, Corless C, et al. Expression of cell cycle-regulated proteins in prostate cancer. Cancer Res. 1996;56:4159-4163.
33. Betticher DC, Heighway J, Thatcher N, et al. Abnormal expression of CCND1 and RB1 in resection margin epithelia of lung cancer patients. Br J Cancer. 1997;75:1761-1768.
34. Takano Y, Kato Y, van Diest PJ, et al. Cyclin D2 overexpression and lack of p27 correlate positively and cyclin E inversely with a poor prognosis in gastric cancer cases. Am J Pathol. 2000;156:585-594.
35. Moore JD, Kornbluth S, Hunt T. Identification of the nuclear localization signal in Xenopus cyclin E and analysis of its role in replication and mitosis. Mol Biol Cell. 2002;13:4388-4400.
36. Jackman M, Kubota Y, den Elzen N, et al. Cyclin A- and cyclin E-Cdk complexes shuttle between the nucleus and the cytoplasm. Mol Biol Cell. 2002;13:1030-1045.
37. Willmarth NE, Albertson DG, Ethier SP. Chromosomal instability and lack of cyclin E regulation in hCdc4 mutant human breast cancer cells. Breast Cancer Res. 2004;6:R531-R539.